|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29.08.25 - 23:48
|
Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development (Business Wire)
|
|
|
– Dr. Aftab has served for over 25 years at Exelixis and has been instrumental in driving the company's scientific innovation and development activities –ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced it has appointed Dana T. Aftab, Ph.D., as its Executive Vice President, Research and Development. In this new role, Dr. Aftab will oversee all aspects of the company's drug discovery, translational research, product development and medical affairs activities.
"Dana has been an integral part of the Exelixis team for more than 25 years, with deep expertise that spans the drug discovery and development continuum. He's been a key contributor to many of Exelixis' most important milestones, including the discovery, development and introduction of cabozantinib, which he and the broader Exelixis team grew from an initial orphan drug indication into a global oncology franchise,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. “Dana i...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
